JAMES WAYNE HANSEN, M.D., PH.D.
Medical Practice at Spring Park Dr, Evansville, IN
License number
Indiana 01030591A
Category
Medical Practice
Type
Pediatrics
Address
Address
5600 Spring Park Dr, Evansville, IN 47711
Phone
(812) 454-5813
Personal information
See more information about JAMES WAYNE HANSEN at radaris.comName
Address
Phone
6061 County Road 700 N, North Salem, IN 46165
66 Worth Ave, Indianapolis, IN 46224
Professional information
Dr. James W Hansen, Evansville IN - MD (Doctor of Medicine)
Specialties:
Neonatal Medicine
Address:
Mead Johnson, Evansville 47721
(812) 429-7417 (Phone), (812) 429-7483 (Fax)
(812) 429-7417 (Phone), (812) 429-7483 (Fax)
Certifications:
Pediatrics, 1976, Perinatal Medicine & Neonatal Medicine, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of California At San Francisco
Moffitt Hosp
Georgetown
University of California At San Francisco
Moffitt Hosp
Georgetown
Method To Reduce The Incidence Of Intraventricular Hemorrhage In Preterm Infants
US Patent:
6753350, Jun 22, 2004
Filed:
Mar 24, 2003
Appl. No.:
10/395356
Inventors:
James W. Hansen - Evansville IN
Karen H. Knauff - Newburgh IN
Deborah A. Schade - Evansville IN
Karen H. Knauff - Newburgh IN
Deborah A. Schade - Evansville IN
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 3120
US Classification:
514560
Abstract:
A method for reducing the incidence of Intraventricular Hemorrhage in preterm infants, involving the administration to those infants of a combination of docosahexaenoic acid and arachidonic acid.
Use Of Docosahexaenoic Acid And Arachidonic Acid Enhancing The Growth Of Preterm Infants
US Patent:
2004017, Sep 2, 2004
Filed:
Nov 14, 2003
Appl. No.:
10/713936
Inventors:
Deborah Schade - Evansville IN, US
Kimberly Merkel - Evansville IN, US
James Hansen - Evansville IN, US
Kimberly Merkel - Evansville IN, US
James Hansen - Evansville IN, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K047/00, A61K031/202
US Classification:
424/439000, 514/560000
Abstract:
A method for enhancing the growth of preterm infants involving the administration of certain long chain polyunsaturated fatty acids. It is preferred that the infants are administered an infant formula containing a combination of docosahexaenoic acid and arachidonic acid.
Liquid Nutritional Product To Supplement Human Milk
US Patent:
2006023, Oct 19, 2006
Filed:
Apr 15, 2005
Appl. No.:
11/106830
Inventors:
Gabor Puski - Newburgh IN, US
James Hansen - Evansville IN, US
John Euber - Evansville IN, US
James Hansen - Evansville IN, US
John Euber - Evansville IN, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - PRINCETON NJ
International Classification:
A23L 1/30
US Classification:
426072000
Abstract:
The present invention relates to a commercially sterile liquid nutritional supplement for human milk for feeding infants such as premature or “failure to thrive” infants. The supplement is highly concentrated in order to produce a supplemented human milk that meets the nutritional needs of premature or “failure to thrive” infants in a volume that is well tolerated by the infants. The present invention relates also to methods to support the rapid growth of premature or “failure to thrive” infants by administering the nutritional supplement described herein to such infants.
Tolerance Nutritional Product To Supplement Human Milk
US Patent:
2003017, Sep 18, 2003
Filed:
Feb 4, 2003
Appl. No.:
10/358081
Inventors:
John Euber - Evansville IN, US
James Hansen - Evansville IN, US
James Hansen - Evansville IN, US
International Classification:
A61K035/20, A61K031/70
US Classification:
424/535000, 514/023000
Abstract:
The invention relates to a nutritional supplement for human milk to feed premature infants comprising protein, fat and carbohydrates wherein the carbohydrate content is limited to no more than about 10% dry weight of the nutritional supplement, and the fat content is at least about 35% dry weight, to reduce the increase in osmolality occurring when the supplement is added to human milk and, thus, produce a supplemented human milk that is better tolerated by the infants. Vitamins and minerals can be added. The present invention relates also to methods to support the rapid growth of premature infants by administering nutritionally supplemented human milk to those infants.
Nutritional Compositions Containing Vitamin D Esters
US Patent:
5422127, Jun 6, 1995
Filed:
Dec 21, 1992
Appl. No.:
7/993997
Inventors:
David G. Dube - Newburgh IN
John R. Euber - Evansville IN
James W. Hansen - Evansville IN
Andrew C. Mosier - Evansville IN
Joseph L. Napoli - Amhurst NY
Gwen G. Richardson - Newburgh IN
John R. Euber - Evansville IN
James W. Hansen - Evansville IN
Andrew C. Mosier - Evansville IN
Joseph L. Napoli - Amhurst NY
Gwen G. Richardson - Newburgh IN
Assignee:
Bristol-Myers Squibb Company - New York NY
International Classification:
A23L 1303
US Classification:
426 73
Abstract:
The present invention is directed to nutritional compositions at an acidic to mid pH containing a vitamin D ester, an amino acid source, a carbohydrate source and a certain amount of a lipid source. The compositions have improved vitamin D stability upon storage.
Composition And Method For Viral Inhibition
US Patent:
2004019, Sep 30, 2004
Filed:
Mar 28, 2003
Appl. No.:
10/401390
Inventors:
Mary Locniskar - Lawrence KS, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Evansville IN, US
James Hansen - Evansville IN, US
Steven Rumsey - Evansville IN, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Evansville IN, US
James Hansen - Evansville IN, US
Steven Rumsey - Evansville IN, US
International Classification:
A61K031/7012, A61K047/00
US Classification:
424/439000, 514/053000
Abstract:
A method for inhibiting Rotavirus infection by administering effective amount of lactulose is provided. Lactulose can be administered alone, in combination with other nutrient supplements such as vitamins, or as part of a nutritional product such as infant formula.
Nutritional Formula For Premature Infants And Method Of Making
US Patent:
6162472, Dec 19, 2000
Filed:
Apr 1, 1999
Appl. No.:
9/283642
Inventors:
M. Pamela Griffin - Charlottesville VA
James W. Hansen - Evansville IN
James W. Hansen - Evansville IN
Assignee:
University of Virginia Patent Foundation - Charlottesville VA
International Classification:
A23C 9127
US Classification:
426 42
Abstract:
A milk based formula for premature infants has been discovered. The formula has a reduced lactose content, preferably less than 20%. Premature and low birth-weight infants fed the infant formula demonstrate improved feeding tolerance.
Composition And Method For Viral Inhibition
US Patent:
2005001, Jan 20, 2005
Filed:
Jul 8, 2004
Appl. No.:
10/886760
Inventors:
Mary Locniskar - Lawrence KS, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Evansville IN, US
James Hansen - Evansville IN, US
Steven Rumsey - Evansville IN, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Evansville IN, US
James Hansen - Evansville IN, US
Steven Rumsey - Evansville IN, US
International Classification:
A61K031/7012, A61K047/00
US Classification:
514053000, 424439000
Abstract:
A method for inhibiting infection by administering effective amount of lactulose is provided. Lactulose can be administered alone, in combination with other nutrient supplements such as vitamins, or as part of a nutritional product such as infant formula.
Composition And Method For Viral Inhibition
US Patent:
2005027, Dec 15, 2005
Filed:
May 26, 2005
Appl. No.:
11/138585
Inventors:
Mary Locniskar - Lawrence KS, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Freeland WA, US
James Hansen - Evansville IN, US
Bryon Petschow - Newburgh IN, US
Robert Burns - Evansville IN, US
Virginia Sickles - Freeland WA, US
James Hansen - Evansville IN, US
International Classification:
A61K031/7012, A61K039/15
US Classification:
424439000, 514053000
Abstract:
A method for inhibiting Rotavirus infection by administering effective amount of lactulose is provided. Lactulose can be administered alone, in combination with other nutrient supplements such as vitamins, or as part of a nutritional product such as infant formula.